In-vivo Evaluation of DT386-BR2, A Promising Anticancer Fusion Protein, in Mice Model

Document Type : Original Article (s)

Authors

1 Pharmaceutical Biotechnologist, Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Pharmacy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor, Department of Pharmaceutical Biotechnology AND Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Cancer is one of the greatest health-related problems and due to increasing drug resistance and severe side effects of chemotherapeutic agents, production of targeted anticancer agents with lower side effects is under consideration. Previously, we produced a fusion protein consisted of catalytic and translocation domains of diphtheria toxin (DT386) fused to BR2, a cancer specific cell penetrating peptide. First steps of this study showed selective antiproliferative effects of DT386-BR2 on cancer cells but not on normal cell lines. The aim of the present study was evaluation of its in-vivo non-specific toxicity in healthy mice.Methods: The fusion protein was produced and purified through recombinant DNA technology. Intraperitoneal injections with various concentrations of DT386-BR2 were done in healthy mice for five consecutive days and they observed for 14 days after the last injection inspecting their food consumption, body weight, body temperature, and finally being dead or alive. Negative controls were injected with normal saline solution.Findings: There was not any significant effect on temperature, body weight, and viability of mice received various concentrations of DT386-BR2 (P < 0.05), and increasing the protein concentration did not show any adverse effects on mice.Conclusion: DT386-BR2 can be used for further pre-clinical studies to determine its pharmacokinetics/pharmacodynamics profiles and evaluation of its anticancer efficacy in suitable xenograft animal models.

Keywords

References

  1. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 2001; 81: 93-124.
  2. Bustillo ME. A Modular Approach to the characterization of histone H2A-derived antimicrobial peptides [Thesis]. Wellesley, MA: Wellesley College; 2013.
  3. Pavia KE, Spinella SA, Elmore DE. Novel histone-derived antimicrobial peptides use different antimicrobial mechanisms. Biochim Biophys Acta 2012; 1818(3): 869-76.
  4. Lee HS, Park CB, Kim JM, Jang SA, Park IY, Kim MS, et al. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett 2008; 271(1): 47-55.
  5. Shapira A, Benhar I. Toxin-based therapeutic approaches. Toxins (Basel) 2010; 2(11): 2519-83.
  6. Lim KJ, Sung BH, Shin JR, Lee YW, Kim DJ, Yang KS, et al. A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS One 2013; 8(6): e66084.
  7. Shafiee F, Rabbani M, Jahanian-Najafabadi A. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent. J Microbiol Methods 2016; 130: 100-5.
  8. Savar NS, Jahanian-Najafabadi A, Mahdavi M, Shokrgozar MA, Jafari A, Bouzari S. In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections. J Biotechnol 2014; 175: 31-7.
  9. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
  10. National Research Council. Guide for the care and use of laboratory animals. 7th ed. Washington, DC: The National Academies Press; 2010.
  11. Cha JH, Brooke JS, Eidels L. Toxin binding site of the diphtheria toxin receptor: loss and gain of diphtheria toxin binding of monkey and mouse heparin-binding, epidermal growth factor-like growth factor precursors by reciprocal site-directed mutagenesis. Mol Microbiol 1998; 29(5): 1275-84.
  12. Cha JH, Chang MY, Richardson JA, Eidels L. Transgenic mice expressing the diphtheria toxin receptor are sensitive to the toxin. Mol Microbiol 2003; 49(1): 235-40.
  13. Saito M, Iwawaki T, Taya C, Yonekawa H, Noda M, Inui Y, et al. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat Biotechnol 2001; 19(8): 746-50.
  14. Holmes RK. Biology and molecular epidemiology of diphtheria toxin and the tox gene. J Infect Dis 2000; 181(Suppl 1): S156-S167.
Journal of Isfahan Medical School
Volume 35, Issue 433 - Serial Number 433
May and June 2017
Pages 655-661

Files

History

  • Receive Date: 28 June 2017
  • Revise Date: 07 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics